Mark Baldry Sells 29,159 Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) insider Mark Baldry sold 29,159 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $13,121.55. Following the completion of the transaction, the insider now owns 94,123 shares in the company, valued at approximately $42,355.35. This trade represents a 23.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

X4 Pharmaceuticals Trading Up 3.0 %

Shares of XFOR traded up $0.01 during trading hours on Monday, hitting $0.49. 2,333,226 shares of the stock traded hands, compared to its average volume of 2,696,270. The business has a fifty day moving average of $0.55 and a 200-day moving average of $0.61. The firm has a market capitalization of $83.84 million, a PE ratio of -5.46 and a beta of 0.14. X4 Pharmaceuticals, Inc. has a 1-year low of $0.26 and a 1-year high of $1.60. The company has a current ratio of 4.89, a quick ratio of 4.80 and a debt-to-equity ratio of 1.26.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals during the third quarter worth approximately $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals during the 3rd quarter worth $37,000. XTX Topco Ltd bought a new stake in shares of X4 Pharmaceuticals during the 2nd quarter valued at $65,000. Rhumbline Advisers lifted its stake in shares of X4 Pharmaceuticals by 14.6% in the 2nd quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock valued at $109,000 after purchasing an additional 23,831 shares during the period. Finally, Jane Street Group LLC boosted its position in shares of X4 Pharmaceuticals by 103.4% in the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after purchasing an additional 126,296 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on XFOR shares. Stifel Nicolaus reduced their target price on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. HC Wainwright reissued a “buy” rating and issued a $1.50 price objective on shares of X4 Pharmaceuticals in a research note on Tuesday, January 14th.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.